In a host cell that does not manufacture the protein, the virus is unable to reproduce (apparently the jargon for this is "replication-defective"). So the virus particles manufactured above can be injected with little risk of infection.
What these guys have done is broken that real Ebola into two pieces, where one piece is only in the monkeys. So even in the worst case scenario that a monkey infects a human with "real" Ebola when they are testing the vaccine efficiency, the "real" Ebola is now unable to replicate itself in the human body. It's very clever.
Edit: so I think the answer by k_sze is wrong, but I'm not sure. Is there an immunologist in the room?
http://www.sciencemag.org/content/early/2015/03/25/science.a...
Previously, we showed that a whole EBOV vaccine based on a replication-defective EBOV (EBOVΔVP30) protects immunized mice and guinea pigs against lethal challenge with rodent-adapted EBOV.
edit: to be clear, k_sze is not wrong, they tested the vaccine against active virus.
Why does this work?